ProCE Banner Activity

Noninvasive Tests for NASH

Podcast Episodes
Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests for NASH.

Released: July 07, 2020

Expiration: July 06, 2021

Share

Faculty

Stephen A. Harrison

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Provided by

Provided by the American Gastroenterology Association.
ProCE Banner

Supporters

Supported by educational grants from

Allergan

Gilead

Intercept Pharmaceuticals

Partners

Endocrine Society

ProCE Banner

Faculty Disclosure

Primary Author

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Akero, Altimmune, Axcella, Blade Therapeutics, Cirius, CiVi Biopharma, Contravir, Cymabay, Echosens, Fortress Bio, Galectin, Galmed, Gelesis, Genfit, Gilead Sciences, HighTide, HistoIndex, Indalo, Innovate, Intercept, Madrigal, Medpace, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, Perspectum, Poxel, Prometheus, Prometic,Terns, Viking, and 3V Bio; has received funds for research support from Axcella, Bristol-Myers Squibb, Cirius, Conatus, Contravir, Cymabay, Envyo, Galectin, Galmed, Genfit, Gilead Sciences, HighTide, Immuron, Intercept, Madrigal, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, Pfizer, Second Genome, Tobira/Allergan, and 3V Bio; and has stock ownership or equity in Akero, Galectin, Genfit, Madrigal, Metacrine, NGM, and NorthSea.

Staff Disclosure

Staff

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.